|
|
Volumn 33, Issue 3, 2015, Pages 219-221
|
|
Amgen's bispecific antibody puffs across finish line
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BISPECIFIC ANTIBODY;
BLINATUMOMAB;
CATUMAXOMAB;
DULIGOTUZUMAB;
ACUTE GRANULOCYTIC LEUKEMIA;
ACUTE LYMPHOBLASTIC LEUKEMIA;
ADVANCED CANCER;
AUTOIMMUNE DISEASE;
B CELL LEUKEMIA;
COLORECTAL CANCER;
DRUG MARKETING;
EUROPEAN MEDICINES AGENCY;
GASTROINTESTINAL CARCINOMA;
HEMOPHILIA A;
HODGKIN DISEASE;
HUMAN;
IMMUNOGENICITY;
LEUKEMIA;
LUNG FIBROSIS;
NOTE;
OSTEOARTHRITIS;
PRIORITY JOURNAL;
PROTEIN ENGINEERING;
PROTEIN EXPRESSION;
RHEUMATOID ARTHRITIS;
SOLID TUMOR;
STOMACH CANCER;
CLINICAL TRIAL (TOPIC);
DRUG INDUSTRY;
IMMUNOLOGY;
NATURAL KILLER CELL;
ANTIBODIES, BISPECIFIC;
CLINICAL TRIALS AS TOPIC;
DRUG INDUSTRY;
HUMANS;
KILLER CELLS, NATURAL;
|
|
EID: 84924425633
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0315-219 Document Type: Note |
|
Times cited : (30)
|
|
References (0)
|